II
RETA

Ibex Investors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Ibex Investors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-4,239
Closed -$238K – 144
2018
Q4 		$238K Buy
+4,239
New +$259K 0.04% 61

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Ibex Investors's RETA Position: Q1 2019 in Review

Ibex Investors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2019, closing a stake of 4,239 shares — an estimated $238K sold.

Ibex Investors first reported a position in RETA in Q4 2018 and held it in 1 quarter. The position peaked at $238K in Q4 2018. 157 funds tracked by Wall St. Rank hold RETA as of Q1 2019.

  • Ibex Investors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2019 after selling out during the quarter.
  • Ibex Investors sold 4,239 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2019, an estimated $238K.
  • Ibex Investors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2018 and held it in 1 quarter.
  • Ibex Investors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $238K in Q4 2018.
  • 157 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2019.

Based on Ibex Investors's 13F filing for Q1 2019, filed 7 May 2019.